FAM
VRDN icon

Formidable Asset Management’s Viridian Therapeutics VRDN Stock Holding History

Formidable Asset Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-519
Closed -$430K – 338
2019
Q1 		$430K Buy
+519
New +$23.5K 0.17% 108

Other funds holding VRDN

AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Formidable Asset Management's VRDN Position: Q2 2019 in Review

Formidable Asset Management sold out of Viridian Therapeutics (VRDN) in Q2 2019, closing a stake of 519 shares — an estimated $430K sold.

Formidable Asset Management first reported a position in VRDN in Q1 2019 and held it in 1 quarter. The position peaked at $430K in Q1 2019. 46 funds tracked by Wall St. Rank hold VRDN as of Q2 2019.

  • Formidable Asset Management reported no remaining Viridian Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Formidable Asset Management sold 519 Viridian Therapeutics shares in Q2 2019, an estimated $430K.
  • Formidable Asset Management first reported a position in Viridian Therapeutics in Q1 2019 and held it in 1 quarter.
  • Formidable Asset Management's Viridian Therapeutics position peaked at $430K in Q1 2019.
  • 46 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2019.

Based on Formidable Asset Management's 13F filing for Q2 2019, filed 15 Oct 2019.